These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39084081)

  • 1. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies.
    Huang Z; Li L; Cheng B; Li D
    Biomed Pharmacother; 2024 Sep; 178():117218. PubMed ID: 39084081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of class I HDAC modulators: Inhibitors and degraders.
    Huang Z; Zeng L; Cheng B; Li D
    Eur J Med Chem; 2024 Oct; 276():116696. PubMed ID: 39094429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure, Functions and Selective Inhibitors of HDAC6.
    Liang T; Fang H
    Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90).
    Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G
    Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment.
    Gu Z; Lin S; Yu J; Jin F; Zhang Q; Xia K; Chen L; Li Y; He B
    Eur J Med Chem; 2024 Sep; 275():116571. PubMed ID: 38857566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
    Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
    Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design.
    Peng J; Xie F; Qin P; Liu Y; Niu H; Sun J; Xue H; Zhao Q; Liu J; Wu J
    Bioorg Chem; 2023 Sep; 138():106622. PubMed ID: 37244230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
    Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
    Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
    Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
    Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
    Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
    Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders.
    Yang K; Song Y; Xie H; Wu H; Wu YT; Leisten ED; Tang W
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2493-2497. PubMed ID: 29871848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
    Cosenza M; Pozzi S
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
    Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
    Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment.
    Wu TY; Chen M; Chen IC; Chen YJ; Chen CY; Wang CH; Cheng JJ; Nepali K; Chuang KH; Liou JP
    J Adv Res; 2023 Apr; 46():159-171. PubMed ID: 35752438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent innovative advances in the discovery of selective HDAC6 inhibitors.
    T Tavares M; Shen S
    Future Med Chem; 2021 Jun; 13(12):1017-1019. PubMed ID: 33906379
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel class of anthraquinone-based HDAC6 inhibitors.
    Song Y; Lim J; Seo YH
    Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.